# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Leerink Partners analyst Daina Graybosch downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Outperform to Market Perform and...
Jones Trading analyst Soumit Roy downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Hold.
HC Wainwright & Co. analyst Edward White downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Neutral.
Guggenheim analyst Michael Schmidt downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Neutral.